"McKinsey Settles for $78M in Opioid Dispute with Insurers"
Consulting firm McKinsey and Co. has agreed to a $78 million settlement with insurers and health care funds over allegations that its marketing strategies for Purdue Pharma's OxyContin contributed to the opioid addiction crisis. The settlement, pending judicial approval, will establish a fund to reimburse prescription opioid costs. This follows previous settlements by McKinsey, including a nearly $600 million agreement in 2021 with various U.S. states and territories, and a $230 million settlement with school districts and local governments. McKinsey maintains that its past work was lawful but has ceased advising on opioid-related business since 2019.